Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in <i>RET</i> -Altered Solid Tumors: Analysis of the RETgistry Global Consortium
The prevalence of secondary RET mutations after SRI was low, underscoring a greater role for off-target resistance. Recurrent acquired alterations involving tumor suppressor genes or upstream regulators of MAPK and PI3K pathways were identified, most commonly MET amplification. Continued efforts to characterize SRI resistance biology are critical to guide the development of novel therapeutic strategies.
Authors
- Christina J. Falcon (ORCID: https://orcid.org/0000-0001-9143-1639)
- L. J. Wirth
- J. Patel
- Sarah Waliany (ORCID: https://orcid.org/0000-0001-5960-8801)
- Alexander D. Drilon
- Martin Früh
- O. Gautschi
- Natalie F. Uy
- Urs Weber
- Stephen V. Liu (ORCID: https://orcid.org/0000-0002-4852-3914)
- Alissa J. Cooper (ORCID: https://orcid.org/0000-0001-9124-0082)
- Katherine E. Smith (ORCID: https://orcid.org/0009-0004-5114-794X)
- Christina S. Baik (ORCID: https://orcid.org/0009-0007-0822-9060)
- Misako Nagasaka (ORCID: https://orcid.org/0000-0001-5308-615X)
- Andrew Do (ORCID: https://orcid.org/0000-0002-5782-5818)
- H. Loong
- Shetal Patel (ORCID: https://orcid.org/0000-0002-7210-5085)
- Jonathan Wesley Riess (ORCID: https://orcid.org/0000-0001-7370-7304)
- Daniela Weiler (ORCID: https://orcid.org/0009-0007-8059-7861)
- G. Lai
- Tae Min Kim (ORCID: https://orcid.org/0000-0003-0015-2701)
- Tejas Patil (ORCID: https://orcid.org/0000-0003-4389-1010)
- Aaron S. Mansfield
- Justin F. Gainor
- Natasha B. Leighl
- Georg Pall
- S. Ignatius. Ou
- Lova Sun
- Kingsley S. Y. Cheung
- Julia K. Rotow
- Shirish Gadgeel
- Benjamin J. Solomon
- Dae Ho Lee
- Jessica J. Lin
- Daniel S. W. Tan
- Jamie Feng
Institutions
- University of North Carolina at Chapel Hill (US)
- University of Bern (CH)
- Bern University of Applied Sciences (CH)
- Cleveland Clinic (US)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Henry Ford Health System (US)
- University of Lucerne (CH)
- Chinese University of Hong Kong (HK)
- Georgetown University (US)
- University of Washington (US)
- University of California, Irvine (US)
- Cornell University (US)
- Kantonsspital St. Gallen (CH)
- Peter MacCallum Cancer Centre (AU)
- University Hospital of Bern (CH)
- Asan Medical Center (KR)
- Princess Margaret Cancer Centre (CA)
- Seoul National University Hospital (KR)
- Henry Ford Hospital (US)
- University of California, Irvine Medical Center (US)
- Dana-Farber Cancer Institute (US)
- Mayo Clinic in Arizona (US)
- University of Colorado Cancer Center (US)
- Global Cancer Institute (US)
- National Cancer Centre Singapore (SG)
- University of Washington Applied Physics Laboratory (US)
- Mayo Clinic in Florida (US)
- University of North Carolina System (US)
- University Hospital Innsbruck (AT)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- University of Pennsylvania (US)
- University of California, Davis (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-15
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-4382
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00